GridAI Technologies Corp. (GRDX)
GRDX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1604191/000110465926054106/0001104659-26-054106-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GRDX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001604191 |
| SEC industry code | Electric & Other Services Combined |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $36K |
| Net income | -$6.4M |
| Operating income | -$7.1M |
| Net margin | -17634.4% |
| Operating margin | -19540.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $900K |
| Total assets | $48.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 649.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern one year from the date these financial statements are issued." | 10-Q 2026-08-21 |
| Cash and burn | $1.4M cash; operating cash flow -$2.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 7,131,123 (2026-08-31); 4,765,729 a year earlier; 7,152,204 three years earlier. 1y figure adjusted for splits (1-for-3 overall); 3y figure adjusted for splits (1-for-60 overall). | Cover page 2026-08-31 |
| Reverse splits, 3 years | 2; latest 1-for-3 on 2025-08-18 | Source 2025-08-18 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-28 |
| Auditor | Macias Gini & O'Connell LLP, Irvine, California, United States | PCAOB Form AP 2026-05-13 |
| Late filings, 12 months | 4 NT notices | NT 10-Q 2026-08-14 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $86K | -$13.0M | -$1.5M | $1.4M | $1.7M | Needs four quarters | 10-Q/A 2026-09-18 |
| Q1 2026 2026-03-31 | $38K | -$3.4M | -$1.8M | $386K | $2.4M | Needs four quarters | 10-Q 2026-05-27 |
| Q4 2025 2025-12-31 | Not filed | -$3.0M | -$4.0M | $900K | $2.0M | $36K | 10-K 2026-05-01 |
| Q3 2025 2025-09-30 | Not filed | -$1.2M | -$856K | $2.5M | No debt tags | Needs four quarters | 10-Q 2025-11-19 |
| Q2 2025 2025-06-30 | Not filed | -$998K | -$55K | $4K | No debt tags | Needs four quarters | 10-Q 2025-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$1.3M | -$819K | $59K | No debt tags | Needs four quarters | 10-Q 2025-05-15 |
| Q4 2024 2024-12-31 | Not filed | -$12.2M | -$172K | $163K | No debt tags | Needs four quarters | 10-K 2026-05-01 |
| Q3 2024 2024-09-30 | Not filed | -$2.6M | -$1.8M | $367K | No debt tags | Needs four quarters | 10-Q 2025-11-19 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-10-28 |
| Latest annual report | 10-K | 2026-05-01 |
| Latest quarterly / interim | 10-Q/A | 2026-09-18 |
| Latest current report FORM 8-K | 8-K | 2026-10-30 |
| Latest proxy | PRE 14A | 2025-08-26 |
Source: SEC EDGAR submissions feed, 767 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -24.0% |
| 1 month | -17.8% |
| 3 months | -1.3% |
| Year to date | -19.7% |
| 1 year | +1.9% |
| From 52-week high | -45.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| FLNA | Filana Therapeutics Inc. | $0.4700 | +10.56% | $23.6M |
| BYSI | BeyondSpring Inc. | $0.5788 | -3.73% | $23.8M |
| IXHL | Incannex Healthcare Inc. | $1.93 | -2.03% | $24.2M |
| RNAZ | TransCode Therapeutics Inc. | $1.35 | -1.46% | $22.9M |
| IMMP | Immutep Limited | $3.40 | -2.30% | $25.1M |
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier